Abstract: The invention generally relates to environmental friendly pesticide compounds, formulations, methods of preparation and application and utilities thereof. More particularly, the invention relates to pesticide compounds and formulations that include terpenes or terpenoids having chemical formula of (C5H8)n, and its derivatives and analogs thereof, as active insecticidal ingredients; certain botanical essential oils as synergists, and other select ingredients as additives.

Abstract: The invention describes alpha lipoic acid complexes, that can be oligomeric, polymeric, monomeric and mixtures thereof. The complexes can be salts, chelates, etc. of the oligomers, polymers, or monomeric alpha lipoic acid.

Abstract: A skin treatment regimen for delivery of a rinse-off personal skin care composition is provided. The rinse-off personal skin care composition includes varying ratios of a lathering agent to a hydrophobic benefit agent. The rinse-off personal skin care composition can be applied to skin of a user in phases over and/or in a treatment cycle. Each of the phases of the treatment cycle can include a ratio of the varying ratios that can be different such as higher or lower than a ratio of adjacent phase.

Abstract: The present invention relates to a personal care composition. The personal care composition comprises a surfactant phase. The surfactant phase comprises a surfactant of about 3% to about 12%, by weight of the personal care composition and a co-surfactant of about 4% or less by weight of the personal care composition. The surfactant includes sodium trideceth sulfate. The surfactant phase further comprises a structuring system. The structuring system comprises about 0.05% to about 5%, by weight of the personal care composition, of a crosslinked associative polymer and an electrolyte. The crosslinked associative polymer comprises a hydrophobic modification of less than 10% and can be hydrophobically modified with greater than a C6 alkyl. The personal care composition further comprises a benefit phase comprising a hydrophobic benefit material of about 1% to about 50%, by weight of the personal care composition.

Abstract: Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.

Abstract: A non-stoichiometric clathrate of lipid and sulfur has been shown to effectively stabilize nerve cell membranes. As such, said compound has proven useful in a variety of neuropsychiatric disorders such as, addiction, depression, autism, Tourette's syndrome, and the like.

Abstract: Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.

Abstract: A synergistic insecticide is provided by the addition of sodium lauryl sulfate or lecithin to an essential oil, preferably an essential oil which has been deregulated by the Environmental Protection Agency, to enable independently inactive or relatively inactive materials to provide commercially acceptable insecticidal properties without the need for undesirable poisons that may be toxic to humans and pets.

Abstract: The present invention is directed to novel water-soluble prodrugs of aliphatic or aromatic hindered hydroxyl group containing pharmaceuticals.

Abstract: Disclosed herein are microemulsion insecticides that do not contain conventional actives. The microemulsion form permits insects to be killed by an oil/surfactant combination.

Abstract: In accordance with the present invention, there are provided a class of compounds which are capable of selectively modulating processes mediated by peroxisome proliferator activated receptor-gamma (PPAR-.gamma.). The identification of such compounds makes possible the selective intervention in PPAR-.gamma. mediated pathways, without exerting inadvertent effects on pathways mediated by other PPAR isoforms.

Abstract: A highly effective, broad spectrum, quick-acting, nonpoisonous insecticidal composition with synergistic kill ratio and kill time is provided when cornmint oil and sodium lauryl sulfate are combined as the essential active ingredients.

Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-(hydrogen or di (C.sub.1 -C.sub.4)alkylamino)-8-halogen-9-(substituted)-6-demethyl-6-deoxytetracycl ine of Formula I: ##STR1## wherein R, X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to compounds of formula (I) ##STR1## in which: R.sub.f denotes a linear or branched C.sub.6 to C.sub.20 perfluoroalkyl radical or a mixture of linear or branched C.sub.4 to C.sub.20 perfluoroalkyl radicals;m represents 0, 1 or 2;n represents a statistical value or integer between 2 and 10;G represents a unit chosen from: ##STR2## it being possible for each of the oxygen atoms to be linked to a hydrogen atom or to another unit G, to their use as surfactants and also to cosmetic or pharmaceutical compositions and vesicles containing them, and to a process for preparing them.

Abstract: The present invention relates to formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems and to the use of such formulations for the preparation of medicaments which are suitable for curing prostaglandin deficiencies in humans or animal, for example healing or preventing diseases of the gastro-intestinal tract.

Abstract: This invention provides injectable semi-solid formulations comprising a pharmaceutically or veterinary active agent, an oil and a suitable glyceride release modifying agent.